Procter & Gamble Health Ltd
NSE:PGHL

Watchlist Manager
Procter & Gamble Health Ltd Logo
Procter & Gamble Health Ltd
NSE:PGHL
Watchlist
Price: 5 700 INR -0.11% Market Closed
Market Cap: 94.6B INR
Section:
 

Relative Value

The Relative Value of one PGHL stock under the Base Case scenario is hidden INR. Compared to the current market price of 5 700 INR, Procter & Gamble Health Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PGHL Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

10
P/S
P/S
Price to Sales
10
vs History
22
vs Industry
18
Median 3Y
7.3
Median 5Y
7.5
Industry
2.6
Forward
6.9
More Details
39.3
P/E
P/E
Price to Earnings
39.3
vs History
46
vs Industry
10
Median 3Y
37.8
Median 5Y
39.3
Industry
21.4
Forward
28.8
More Details
27.8
P/OCF
P/OCF
Price to OCF
27.8
vs History
85
vs Industry
11
Median 3Y
37.2
Median 5Y
38.6
Industry
16.4
More Details
29.3
P/FCFE
P/FCFE
Price to FCFE
29.3
vs History
92
vs Industry
12
Median 3Y
43.3
Median 5Y
47.7
Industry
22.8
More Details
15.3
P/B
P/B
Price to Book Value
15.3
vs History
31
vs Industry
3
Median 3Y
13.7
Median 5Y
12.8
Industry
2.2
More Details
9.7
EV/S
EV/S
Enterprise Value to Sales
9.7
vs History
22
vs Industry
18
Median 3Y
7
Median 5Y
7.2
Industry
2.9
Forward
6.7
More Details
13
EV/GP
EV/GP
Enterprise Value to Gross Profit
13
vs History
26
vs Industry
20
Median 3Y
10.1
Median 5Y
10.6
Industry
5.5
More Details
27.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
27.3
vs History
39
vs Industry
14
Median 3Y
25.4
Median 5Y
26.1
Industry
13
Forward
20.9
More Details
29.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
29.8
vs History
41
vs Industry
16
Median 3Y
27.5
Median 5Y
29.1
Industry
16.5
Forward
21.1
More Details
26.9
EV/OCF
EV/OCF
Enterprise Value to OCF
26.9
vs History
85
vs Industry
11
Median 3Y
36.1
Median 5Y
37.5
Industry
15.6
More Details
28.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
28.1
vs History
88
vs Industry
12
Median 3Y
41.1
Median 5Y
44.2
Industry
18.7
More Details
21.6
EV/IC
EV/IC
Enterprise Value to IC
21.6
vs History
38
vs Industry
4
Median 3Y
19.8
Median 5Y
19.9
Industry
1.9
More Details

Multiples Across Competitors

PGHL Competitors Multiples
Procter & Gamble Health Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Procter & Gamble Health Ltd
NSE:PGHL
94.6B INR 10 39.3 27.3 29.8
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.6 56.7 38 40.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.5B USD 5.4 19.8 16.2 21.1
CH
Roche Holding AG
SIX:ROG
268.8B CHF 4.4 28.5 12.1 14.2
UK
AstraZeneca PLC
LSE:AZN
219.6B GBP 5.1 31.5 108.7 159.1
US
Merck & Co Inc
NYSE:MRK
277.5B USD 4.3 14.6 10.3 12.2
CH
Novartis AG
SIX:NOVN
219.4B CHF 4.9 19.1 12.1 15.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 15.6 10.9 12.6
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.8B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
IN
Procter & Gamble Health Ltd
NSE:PGHL
Average P/E: 26.7
39.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
56.7
54%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.5
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.5
37%
0.9
US
Merck & Co Inc
NYSE:MRK
14.6
15%
1
CH
Novartis AG
SIX:NOVN
19.1
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.6
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Procter & Gamble Health Ltd
NSE:PGHL
Average EV/EBITDA: 402.6
27.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.1
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.7
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
CH
Novartis AG
SIX:NOVN
12.1
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Procter & Gamble Health Ltd
NSE:PGHL
Average EV/EBIT: 1 715.2
29.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.7
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.1
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5

See Also

Summary
PGHL intrinsic value, competitors valuation, and company profile.
DCF Valuation
PGHL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PGHL stock valuation using valuation multiples.
Wall Street Estimates
PGHL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PGHL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 308,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.